Monitoring peroral anticoagulation therapy in outpatient practice

1.Marder VJ, Ro­so­ve MH, Minning DM. Founda­tion and si­tes of ac­ti­on pf antithrombo­tic agents. Best Practi­ce Mueller RL. First–ge­ne­ra­tion agents: aspi­rin, he­pa­rin and couma­rins. Best Pract Res Clin Haema­tol 2004; 17(1): 3–22.

2.Bick RL, Mu­ra­no G. Phy­sio­lo­gy of He­mosta­sis. Clin Lab Med 1994; 14(4): 677–707.

3.Baglin TP, Ro­se PE and membres of the Haemosta­sis and Thrombo­sis Task Force. Guide­li­nes on Oral Anti­coa­gu­la­tion: 3rd ed. Br J Haema­tol 1998; 101: 374–387.

4.Kessler P. Léč­ba orální­mi anti­koa­gu­lancii. Orion – yhty­mä Oyj, Orion Pharma 2002.

5.Kottke–Marchant K. La­bo­ra­to­ry diagno­sis of he­morrha­gic and thrombo­tic di­sorders. Diagnostic He­ma­to­lo­gy. He­ma­tol Oncol Clin North Am 1994; 8(4): 809–853.

6.Bergmann F, Kochhan L, Budde U. Die he­re­di­tä­re Thrombophi­lie. Fortschritte in der Dia­gnos­tik. Ha­mosta­seo­lo­gie 1999; 19: 77–85.

7.Ha­renberg J, Huhle G, Hoffmann U. Antithrombo­tische The­ra­pie, Mo­derne Be­handlungsstra­te­gien. Internist 1999; 8: 885–893.

8.Jaenecke J. Indi­ka­tionsge­bie­te fur Anti­koa­gu­lantien. Post– und praeo­pe­ra­ti­ve Anti­koa­gu­lantienprophy­la­xe Anti­koa­gu­lanzien– und Fibri­nolzsethe­ra­pie. New York: Georg Thie­me 1996: 142–175.

9.Kha­mashta M, Cuadra­do M, Mu­jic E et al. The ma­na­ge­ment of thrombo­sis in the antiphospho­li­pid syndro­me. N Engl J Med 1995; 332: 993–997.

10.Me­na­jovsky LB. Long–term Treatment of Ve­nous Thromboembo­lism. Treatment of Ve­nous Thromboembo­lism. Conti­nuing Me­di­cal Edu­ca­tion Se­ries 2006: 39–47.

11.Ma­týško­vá M, Penka M. In­ter­ak­ce anti­koa­gu­lačních lé­ků s po­tra­vi­na­mi a potra­vi­no­vý­mi do­plň­ky. In­ter Med Prax 2005; 5: 29–33.

12.Ansell J, Hirsh J, Poller L et al. The Pharma­co­lo­gy and Ma­na­ge­ment of the vi­ta­min K Anta­go­nists. The Se­venth ACCP Kon­fe­ren­ce on Antithrombo­tick and Thrombo­ly­tic the­ra­py. Chest 2004; 126: 204–233.

13.van Aken H, Bo­de C, Da­rius H et al. Anti­coa­gu­la­tion: The Pre­sent and Fu­tu­re. Sta­te–of–the–Art Re­view. Clin Appl Thromb He­most 2001; 7(3): 195–204.

14.Hettia­rachchi T, Lok J, Prins MH et al. Undiagno­sed Ma­lignancy in Pa­tients with Deep Vein Thrombo­sis, Inci­dence, Risk factors, and Diagno­sis. Cancer 1998; 83(1): 180–185.

15.Sba­rou­ni E, Oakley C. Outco­me of pregnancy in wo­men with valve prothe­ses. Br Heart J 1994; 71: 196–201.

16.Le­vi­ne MN, Raskob G, Betty RJ et al. He­morrha­gic Compli­ca­tions of Anti­coa­gu­lant Treatment. The 7th ACCP Confe­rence on Antithrombo­tick and Thrombo­ly­tic the­ra­py. Chest 2004; 126: 287–310.

17.Uti­li­sa­tion des Trai­te­ments antithrombo­ti­ques en pra­ti­que mé­di­ca­le courante, Re­commanda­tions du Grou­pe d°é­tu­des sur l°hé­mosta­se et la thrombo­se (GEHT). Sang Thrombo­se Vasseaux 1996; 8(Nu­mé­ro spe­cial): 1–43.

18.Bick RL. The­ra­py for Ve­nous Thrombo­sis: Guide­li­nes for a Compe­tent and Cost – effecti­ve Approach. Unre­solved Issues and Pro­po­sed Gu­de­li­nes. Clin Appl Thromb He­most 1999; 5(1): 2–9.

19.Laffan M, Tuddenham E. Assessing thrombo­tic risk. BMJ 1998; 317: 520–523.

20.Schulman S, Wahlander K, Lindstrom T et al. For the THRI­VE III Investi­ga­tors. Se­conda­ry pre­vention of ve­nous thromboembo­lism with oral di­rect trombin inhi­bi­tor xi­me­la­gatran. N Engl J Med 2003; 349: 1813–1721.

21.Makris M, Grea­ves M, Phi­lips W et al. Emergency oral anti­coa­gu­lant re­versal: the re­la­ti­ve effi­ca­cy of infu­sions of fresh fro­zen plasma and clotting factor concentra­te on correction of the coagu­lo­pathy. Thromb Haemost 1996; 77: 477–480.

22.Kakkar VV, Lo­renzo F. Pre­vention of ve­nous thromboembo­lism in ge­ne­ral surge­ry. Clin Haema­tol 1998; 11(2): 605–619.

23.Kearon C, Hirsh J. Ma­na­ge­ment of anti­coa­gu­la­tion be­fo­re and after electi­ve surge­ry. N Engl J Med 1997; 336: 1506–1511.

24.Bu­lik O. Pro­ble­ma­ti­ka sto­ma­to­chi­rurgické­ho ošet­ře­ní v prů­bě­hu anti­koa­gu­lační te­ra­pie. Čes Sto­mat 2003; 103(3): 102–106.

25.Bu­lik O. Ex­trak­ce zu­bů a anti­koa­gu­lační te­ra­pie – srov­ná­ní růz­ných po­stu­pů. Prakt Zub Lék 2004; 52(3): 68–77.

26.Schellong SM, Halbritter K. Ma­na­ge­ment of anti­coa­gu­la­tion be­fo­re and after surge­ry in pa­tiens re­cei­ving longterm VKA the­ra­py – oral pre­senta­tion. GSK Thrombo­sis Masterclass, Berlin 2005.

27.Dunn A, Turpie AGG. Pe­rio­pe­ra­ti­ve ma­na­ge­ment of pa­tients on oral anti­coa­gu­lants: a syste­ma­tic re­wiev. Arch Intern Med 2003; 163: 901–908.

28.Kearon C, Lindmarker P, Weitz JI. A Ti­me – Li­mi­ted or an Inde­fi­ni­te–Du­ra­tion Approach to Anti­coa­gu­lant The­ra­py? Contro­versies in Antithrombo­tic The­ra­py. Sym­po­si­um to the 42nd Annual Meeting of ASH. San Francisco 2000.

29.Penka M, Ma­týško­vá M, Bu­li­ko­vá A et al. Pří­pra­va ne­moc­né­ho s dlou­ho­do­bou anti­koa­gu­lační léč­bou v am­bu­lant­ní pra­xi k chi­rurgické­mu vý­ko­nu. In­ter Med Prax 2000; 5: 20–23.

30.Witt DM, Adler MA, Sha­na­han RL et al. Effect of a centra­li­sed cli­ni­cal pharma­cy anti­coa­gu­la­tion servi­ce on the outco­mes of anti­coa­gu­lant servi­ce. Chest 2005; 127: 1515–1522.